Elmind Capital LP acquired a new stake in shares of Septerna, Inc. (NASDAQ:SEPN – Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 49,444 shares of the company’s stock, valued at approximately $1,655,880. Elmind Capital LP owned approximately 0.11% of Septerna as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. TRV GP V LLC bought a new stake in shares of Septerna in the 2nd quarter worth $208,160,143. TRV GP VI LLC acquired a new stake in Septerna during the second quarter worth approximately $141,048,460. Goldman Sachs Group Inc. increased its holdings in Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after purchasing an additional 1,260,409 shares during the period. BlackRock Inc. bought a new stake in Septerna in the 2nd quarter worth about $64,706,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Septerna by 7.4% in the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after buying an additional 104,394 shares in the last quarter.
Insider Activity
In other Septerna news, SVP Daniel D. Long sold 3,334 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $34.47, for a total transaction of $114,922.98. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,323,321.64. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Elizabeth Bhatt sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00. Following the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. This trade represents a 12.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 61,030 shares of company stock worth $2,329,666. Corporate insiders own 5.80% of the company’s stock.
Septerna Price Performance
Septerna (NASDAQ:SEPN – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The business had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Analysts expect that Septerna, Inc. will post -1.41 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on SEPN shares. Truist Financial increased their target price on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Stifel Nicolaus set a $49.00 price target on Septerna in a research note on Tuesday, August 11th. Guggenheim upped their target price on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. JonesTrading lifted their target price on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.44.
View Our Latest Stock Analysis on SEPN
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Recommended Stories
- Five stocks we like better than Septerna
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
